Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Multiple trials have shown the efficacy of estrogen therapy in metastatic prostate cancer,
and most recently trials have supported the use of transdermal estrogens (patch) in the
patient population with a decreased risk of cardiovascular disease as compared to the oral
estrogens. We plan to study the use of transdermal estrogen at a dose of 0.4mg qd. We will
evaluate the toxicities and measure quality of life. We will assess PSA response and
measurable disease response. This will be a trial available to the Cancer Institute of New
Jersey Oncology Group. We will enroll a total of 33 patients. We will plan to enroll 10 at
CINJ.Patients will wear the patches (4) continuously. We will obtain blood work and clinic
evaluations every three weeks. We will assess quality of life through a questionnaire given
to patient every three weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey